Arvinas, Inc. - ARVN
About Gravity Analytica
Recent News
- 04.23.2025 - Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- 04.23.2025 - Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- 04.23.2025 - Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- 04.21.2025 - Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
- 04.21.2025 - Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
- 04.04.2025 - Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
- 04.04.2025 - Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
- 03.27.2025 - Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
- 03.27.2025 - Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
- 03.13.2025 - Barclays 27th Annual Global Healthcare Conference